Priovant Launches Phase 2b/3 Trial for Brepocitinib in Lichen Planopilaris
Event summary
- Priovant initiates Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare, scarring hair loss disorder with no FDA-approved treatments.
- First subjects enrolled in March 2026; LPP is the fourth late-stage indication for brepocitinib, following dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis.
- Brepocitinib's NDA for dermatomyositis under FDA Priority Review with PDUFA target action date in Q3 2026.
- Priovant aims to build a multi-indication rheum-derm rare disease franchise with overlapping prescriber bases.
The big picture
Priovant's expansion into LPP aligns with its strategy of targeting high-morbidity orphan conditions with limited treatment options. The company is positioning brepocitinib as a cornerstone therapy in a multi-indication rare disease franchise, leveraging its distinctive mechanistic benefits. Success in LPP could further solidify Priovant's role in the autoimmune and inflammatory disease space, particularly as it awaits potential FDA approval for dermatomyositis later this year.
What we're watching
- Regulatory Momentum
- Whether the FDA Priority Review for brepocitinib in dermatomyositis will lead to accelerated approval and set a precedent for other indications.
- Pipeline Diversification
- The pace at which Priovant can advance brepocitinib across multiple rare disease indications and capture overlapping prescriber markets.
- Clinical Efficacy
- How brepocitinib's dual JAK1/TYK2 inhibition mechanism will perform in LPP, given the lack of existing FDA-approved therapies for this condition.
Related topics